Who are Polivy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Polatuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/polatuzumab-vedotin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Polivy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Polivy (POLATUZUMAB VEDOTIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed B-cell antigen receptor complex-associated protein beta chain Oncology Antibody drug conjugate Live · refreshed every 30 min

Target snapshot

Polivy (POLATUZUMAB VEDOTIN) — Roche. Polivy works by binding to a protein on the surface of cancer cells and releasing a toxin that kills the cell.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Polivy TARGET	POLATUZUMAB VEDOTIN	Roche	marketed		B-cell antigen receptor complex-associated protein beta chain	2019-01-01
Polatuzumab	Polatuzumab	National Cancer Institute (NCI)	marketed		B-cell antigen receptor complex-associated protein beta chain, Tubulin beta

Recent regulatory actions (last 90 days)

2026-03-18 — Polatuzumab · FDA · approved · US · National Cancer Institute (NCI)
2026-03-18 — Polivy · FDA · approved · US · Roche

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Polivy — Competitive Intelligence Brief. https://druglandscape.com/ci/polatuzumab-vedotin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab